Heron Therapeutics Inc (HRTX)

Over the past six months, Heron Therapeutics' stock price has been influenced by several events. In February 2026, the stock price passed above its 200-day moving average. In January 2026, the stock rose following strong preliminary fourth-quarter and full-year 2025 revenue growth, with ZYNRELEF contributing significantly. In November 2025, the company announced its Q3 2025 financial results, reporting net revenue of $38.2 million and reaffirmed its 2025 net revenue guidance. Despite positive news, the stock price has generally declined, experiencing a 28.65% decrease between February 5, 2025, and February 4, 2026.

The provided information does not explicitly state any specific demand seasonality for Heron Therapeutics' products and services. Demand for the company's medical treatments may be relatively consistent rather than highly seasonal. The company has reported consistent revenue growth for its acute care franchise, with ZYNRELEF and APONVIE showing strong increases in Q3 2025, driven by commercial initiatives rather than seasonal factors.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing treatments for unmet medical needs, particularly in pain management and supportive care. The company utilizes its Biochronomer drug delivery technology to create extended-release formulations. Key products include ZYNRELEF for postoperative pain, APONVIE for postoperative nausea and vomiting, CINVANTI for chemotherapy-induced nausea and vomiting, and SUSTOL for chemotherapy-induced nausea and vomiting.

Heron Therapeutics primarily serves the U.S. market but is pursuing global partnerships to expand its geographic reach.

Heron Therapeutics has a "Hold" consensus rating from analysts, with an average price target of $4.50. The company's financial health is in the "Yellow zone," indicating a significant pullback but within expected volatility. The company has experienced a decline in revenue from SUSTOL due to competition from generic alternatives. ZYNRELEF is considered a strong product, but initial underperformance and substantial investments have been noted as potential challenges. Recent commercial initiatives have driven significant revenue growth for ZYNRELEF.

Heron Therapeutics has significant institutional ownership, with 265 institutional owners and shareholders holding 80.01% of the company. Major institutional owners include Rubric Capital Management LP, Adage Capital Partners Gp, L.l.c., and BlackRock, Inc. Individual insiders who own company stock include Adam Morgan, Craig A Collard (CEO), Ira Duarte, and William P Forbes. Adam Morgan and Rubric Capital Management LP made significant buy transactions in August 2025.